

From immune suppression to immune modulation in type 1 diabetes patients

Megen, K.M. van

Citation

Megen, K. M. van. (2021, October 5). *From immune suppression to immune modulation in type 1 diabetes patients*. Retrieved from https://hdl.handle.net/1887/3214562

Version:	Publisher's Version
License:	Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from:	https://hdl.handle.net/1887/3214562

Note: To cite this publication please use the final published version (if applicable).

STELLINGEN

behorende bij het proefschrift

From Immune Suppression to Immune Modulation in Type 1 Diabetes Patients

Kayleigh Montana van Megen

- 1. Type 1 diabetes can be reversed by immunotherapy
- 2. Autologous hematopoietic stem cell transplantation is an effective treatment in a select group of T1D patients and should be considered through informed decision making *(this thesis)*
- 3. Tolerogenic dendritic cells are stable and reproducible cellular products as candidate immune modulators (*this thesis*)
- 4. Activated mesenchymal stromal cells can function as antigen-specific immune modulators (*this thesis*)
- 5. Pancreas-derived mesenchymal stromal cells could improve the microenvironment of the islets of Langerhans (this thesis)
- 6. T1D could be re-classified in a 6-stage system that encompasses the full scope of disease and to encourage the discovery of disease-modifying drugs
- 7. Beta cell mass does not equal function
- 8. *Cure sometimes, treat often, comfort always. (Hippocrates)* The goal of T1D therapy should emphasize improving quality of life with less long-term complications alongside finding a cure
- Life is like riding a bicycle. To keep your balance, you must keep moving. (Albert Einstein, 1879-1955) Move forward, innovate, progress, and let go of dogmas.